SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

30 Jul 2020 07:00

RNS Number : 5073U
James Halstead PLC
30 July 2020
 

 

 

 

30 July 2020

 

Pre-Close Trading Statement and Update on Interim Dividend

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2020.

 

Since the Interim Report issued on 31 March much has happened. As we went into the early stages of the pandemic we were conscious of how cash flow would be affected and accordingly took decisive action on spending. Capital expenditure was curtailed, and all discretionary expenses such as marketing were cut. Spending on safety measures increased to ensure our sites were more Covid-19 resistant. Initially a primary concern was cash inflow and it is pleasing to report that customers did not, in general, hold up payments and that the various initiatives by governments in the territories in which we operate provided liquidity. At 30 June 2020 cash balances are slightly ahead of the levels at 31 December 2019. The countries in which our businesses were completely closed were few, with New Zealand being the most significant. There were several UK and international government cash flow initiatives in which we participated - the most significant being the VAT deferral in the UK (March - June) and in Germany (April - June). The German deferral was paid in June and at the end of June the UK deferral amounts to around £1.9 million.

 

Looking now at how our businesses have been affected in more detail:

 

The UK, which represents around 30-35% of turnover, faced significant disruption: almost all of our customers are distributors and through April and into May many were closed. Turnover, in the UK, in those months dropped by up to 65% (versus the comparable period last year) but we continued production to focus on the type of product that was anticipated to remain in demand. In June the UK turnover had recovered to approximately 80% of the prior year.

 

Our direct exports (i.e. to non- Group companies) continued with only a 5 - 10% reduction versus last year in the April- May period. In terms of our overseas based businesses most continued to trade, albeit it with reduced manning levels. In the core lock-down period (i.e. April- May) sales were broadly 20% below the prior year comparative with the full lock-down of New Zealand having an effect. In June our overseas businesses recovered to 90% of the prior year.

 

The preparations made by many governments for the onset of the pandemic did lead to an uplift in the sales of our product to the health and medical research sectors. Normally this sector would represent around 30% of our sheet vinyl sales but from April to June it was much more significant. As well as the supply of sheet vinyl to the NHS across the UK and significant supplies to Ireland, we have supplied new hospital facilities across the globe including Brazil, Argentina, Chile, Mexico, Italy, South Africa, Qatar and the UAE. This was not sufficient to offset the shortfall in business of other sectors which were closed.

 

In terms of overall turnover during the period April to June we averaged just over 70% of the prior year. In terms of the bottom line in this period, profit before tax was just under 50% of the prior year comparative. Cash levels have been preserved.

 

July has seen the position in terms of trading continue to improve as the distribution base in the UK started to fully re-open and in recent weeks we have seen UK sales average over 90% of the comparative. Looking at our main businesses overseas (Germany, Australia and New Zealand) the level is near parity with the comparatives.

 

It is still too early to be confident that the worst is over but it is clear that, to date, this situation is far better than we envisaged four months ago. This has been one of the most testing periods in our long history and many of our staff have put in the most commendable of efforts mobilising direct shipments not just across the UK but to far parts of the world. Whether it was the drivers and warehouse staff coming in late on a bank holiday weekend to ship Polyflor to the NHS or the health and safety teams keeping our people safe - our thanks.

 

Finally, in our Interim Statement our Chairman noted that we would declare a first interim dividend of 2.125p per share representing half the dividend we would otherwise have declared and to review a second equivalent payment of a second interim. These dividends reflected a first half year of record sales and profit. Given the improvement in trading conditions and the cash levels we, as a Board, are sufficiently confident now to declare a second interim dividend of 2.125p which will be payable on 10 September 2020 to shareholders on the register at 21 August 2020.

 

  

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

James Halstead plc

Telephone: 0161 767 2500

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

 

 

 

Hudson Sandler

Telephone: 020 7796 4133

Nick Lyon

 

Nick Moore

 

 

 

Panmure Gordon (Nominated advisor and broker)

Telephone: 020 7886 2500

 

 

Dominic Morley

 

 

 

WH Ireland (Broker)

 

Ben Thorne

Chris Hardie

Telephone: 020 7614 5900

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLKLFLBDLZBBF
Date   Source Headline
16th Aug 20073:00 pmRNSAIM Rule 26
25th Jul 20077:00 amRNSPre-close Trading Update
24th Jul 20074:18 pmRNSDirectors' Dealings
29th Jun 200711:02 amRNSTotal Voting Rights
12th Jun 20074:19 pmRNSDirector/PDMR Shareholding
3rd May 200711:33 amRNSTrading Statement
26th Apr 20074:52 pmRNSBlock listing returns
28th Mar 20077:01 amRNSInterim Results
14th Mar 20074:47 pmRNSNotice of Results
21st Dec 20065:43 pmRNSTotal Voting Rights
4th Dec 200612:23 pmRNSDividend Declaration
1st Dec 20067:01 amRNSAGM Statement
15th Nov 20067:30 amRNSSite visit
18th Oct 20067:01 amRNSIssue of Shares
17th Oct 200610:43 amRNSIssue of Shares
22nd Sep 20067:00 amRNSPreliminary Results
12th Sep 200610:47 amRNSNotice of Results
3rd Jul 20068:44 amRNSChange of Adviser
30th Mar 200611:29 amRNSDirector's shareholding
30th Mar 20067:01 amRNSInterim Results
2nd Mar 20067:01 amRNSNotice of Results
27th Feb 20067:00 amRNSShare sub-division
9th Feb 20062:26 pmRNSShare sub-division
11th Jan 20061:06 pmRNSDirector's shareholding
9th Jan 20062:59 pmRNSGrant of options
6th Jan 200612:58 pmRNSExercise of options etc.
2nd Dec 20058:00 amRNSAGM Statement
2nd Nov 20057:00 amRNSExercise of options etc.
14th Oct 20054:18 pmRNSDirector's shareholding
4th Oct 20057:00 amRNSFinal Results
16th Sep 20053:09 pmRNSNotice of Results
14th Sep 20052:57 pmRNSNotice of Results
3rd Aug 20059:21 amRNSBlock listing application
1st Jun 200512:14 pmRNSBlocklisting Interim Review
4th May 20052:32 pmRNSDirector Shareholding
30th Mar 20057:00 amRNSInterim Results
24th Mar 20059:13 amRNSNotice of Results
14th Jan 20057:00 amRNSB Share and C Share Elections

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.